Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price dropped 1.8% on Wednesday. The stock traded as low as GBX 5.40 and last traded at GBX 5.50. Approximately 1,291,653 shares were traded during trading, a decline of 45% from the average session volume of 2,352,387 shares. The stock had previously closed at GBX 5.60.
Shield Therapeutics Trading Down 1.8%
The business has a 50-day moving average price of GBX 4.90 and a 200-day moving average price of GBX 6.30. The company has a quick ratio of 2.16, a current ratio of 0.75 and a debt-to-equity ratio of -146.28. The firm has a market capitalization of £59.08 million, a P/E ratio of -5.50 and a beta of 1.77.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
